NeuroOne Medical Technologies (NeuroOne) has announced the first robotic neurosurgery case using its Evo sEEG electrode.

The procedure was conducted by Dr William Bingaman at Cleveland Clinic. It is claimed to be the first clinical case to use NeuroOne’s Evo sEEG electrode, available exclusively through Zimmer Biomet in the US.

The electrode was combined with Zimmer Biomet’s ROSA One Brain, a robotic platform designed to aid surgeons in the planning and execution of complex minimally invasive neurosurgical procedures.

NeuroOne CEO Dave Rosa said: “This clinical case utilising our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet.

“Now that Zimmer Biomet has commenced US distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet’s robotics platform which was the foundation of our interest to partner with Zimmer Biomet.”

The Evo sEEG electrode technology is used for stereoelectroencephalography (sEEG) recording and brain stimulation. It also has the potential to support future capabilities for spinal cord stimulation and the future development of ablation solutions for patients with conditions such as Parkinson’s disease, epilepsy and chronic back pain.

In October last year, NeuroOne secured 510(k) approval from the US Food and Drug Administration to commercialise its Evo sEEG electrode technology.

It is intended for temporary (less than 30 days) use with recording, monitoring and stimulation equipment to record, monitor and stimulate electrical signals at the subsurface level of the brain.

NeuroOne offers minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions.